IGH/cMYC (MYC) Translocation, Dual Fusion
- cMYC, 8q24.21, Red
- IGH, 14q32.33, Green
The IGH/cMYC product consists of probes, labelled in green, covering the Constant and Variable segments of the IGH gene, and cMYC probes, labelled in red. The cMYC probe mix contains a 220kb probe centromeric to the cMYC (MYC) gene and a second probe covering the 186kb region telomeric to the cMYC gene, including the D8S1644 marker.
The t(8;14)(q24;q32) translocation involving the IGH (immunoglobulin heavy locus) gene at 14q32.33 and the MYC (MYC proto-oncogene, bHLH transcription factor) oncogene at 8q24 is a recognised recurrent abnormality commonly seen in patients with B-cell malignancy.
IGH-MYC rearrangements are detected in up to 85% of cases of Burkitt lymphoma at diagnosis1. They are also seen in diffuse large B- cell lymphoma (DLBCL)2, multiple myeloma and plasmablastic lymphoma3,4.
In an IGH-MYC rearrangement the translocation breakpoints on chromosome 14 are clustered to a narrow region 5' to the intron enhancer of the immunoglobulin heavy chain, whereas the breakpoints on chromosome 8 can occur more than 340kb upstream of MYC, with no preferential site5. The translocation brings MYC into close proximity to the IGH enhancer and results in the up-regulation of MYC. Over-expression of the transcription factor stimulates gene amplification, resulting in uncontrolled cell proliferation6.
The quality of the products we have received from Cytocell have been excellent. The FISH probes they provide to us give intense, strong signals and are a pleasure to count. What has really stood out however has been the level of support and assistance provided by Cytocell’s application specialists. The team worked very closely alongside our own during the adoption of this product and spent many hours with us perfecting the technique, going above and beyond what I would expect during the transition period. Source BioScience absolutely demand high quality products and service to be able to deliver our results with confidence, and that is what we have received from Cytocell. Neil Ryan, Laboratory Operations Manager at Source BioScience,
- Perkins AS, Friedberg JW, Hematology Am Soc Hematol Educ Program. 2008;341-8
- Ott G, et al., Blood. 2013 Dec 5;122(24):3884-91
- Walker BA, et al., Blood Cancer J. 2014;4(3)
- Elyamany G, et al., Adv Hematol 2015;2015:315289
- Joos et al., Human Molecular Genetics 1992;1(8):625-32
- Erikson J et al., Proc Natl Acad Sci USA 1983;80(3):820-4
- Arsham, MS., Barch, MJ. and Lawce HJ. (eds.) (2017) The AGT Cytogenetics Laboratory Manual. New Jersey: John Wiley & Sons Inc.
- Mascarello JT, Hirsch B, Kearney HM, et al. Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. Genet Med. 2011;13(7):667-675.
- Wiktor AE, Dyke DLV, Stupca PJ, Ketterling RP, Thorland EC, Shearer BM, Fink SR, Stockero KJ, Majorowicz JR, Dewald GW. Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genetics in Medicine. 2006;8(1):16–23.
- Area of Interest*
- ALL, Lymphoma
This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.